ArticleThe European respiratory journal2024
Cystic fibrosis in Europe: improved lung function and longevity - reasons for cautious optimism, but challenges remain.
Article in The European respiratory journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Bridging the Gap in Eastern European Cystic Fibrosis Care: How Newborn Screening and Advanced CFTR Modulation Shape the Clinical Landscape in Western Romania.Children (Basel, Switzerland) · 2026Article
- Toward Precision Electrochemical Sensing of CFTR Function in Cystic Fibrosis Models.Analytical chemistry · 2026Article
- Deep Optic Nerve Head Structural Alterations in Adults with Cystic Fibrosis.Journal of clinical medicine · 2026Article
- Patient-Derived Intestinal Organoids in the Global Cystic Fibrosis Landscape.Pediatric pulmonology · 2026Review
- The New Landscape of Cystic Fibrosis in the Era of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy.Journal of mother and child · 2026Review
- Citrus Flavonoids for Cystic Fibrosis Treatment.Chembiochem : a European journal of chemical biology · 2025Review
- Chronic lung infection byRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Article
- Impact of CFTR Modulators on Longitudinal Cystic Fibrosis Survival and Mortality: Review and Secondary Analysis.Pulmonary therapy · 2025Review
- Respiratory infections after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis: analysis of the European Cystic Fibrosis Society Patient Registry.ERJ open research · 2025Article
- Cystic fibrosis transmembrane conductance regulator therapy with elexacaftor/tezacaftor/ivacaftor reduces detection of hallmark cystic fibrosis pathogens in Europe: progress made but no time to slow down.ERJ open research · 2025Article
- Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis: A Review of Registry-Based Evidence.Journal of clinical medicine · 2025Review
- OvercomingAntibiotics (Basel, Switzerland) · 2025Review
- 20 years of the Montreal Cystic Fibrosis Related Diabetes Screening Cohort: key insights.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Same-Day Repeatability and 28-Day Reproducibility of Xenon MRI Ventilation in Children With Cystic Fibrosis in a Multi-Site Trial.Journal of magnetic resonance imaging : JMRI · 2025Article
- Expanding the Impact of New Cystic Fibrosis Therapies in Low- and Middle-Income Countries.Pediatric pulmonology · 2025Review
- Towards effective cystic fibrosis gene therapy by optimizing prime editing and pulmonary-targeted LNPs.Frontiers in systems biology · 2025Article
- Critical Issues in the Management of CRMS/CFSPID Children: A National Real-World Survey.Pediatric pulmonology · 2025Article
- A Global Perspective on Transition Models for Pediatric to Adult Cystic Fibrosis Care: What Has Been Made So Far?Journal of clinical medicine · 2024Review
- The ageing of people living with cystic fibrosis: what to expect now?European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Cystic fibrosis.Nature reviews. Disease primers · 2024Review
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrognosis and disease severity in cystic fibrosis (CF) are linked to declining lung function. To characterise lung function by the number of adults in countries with different levels of Gross National Income (GNI), data from the European Cystic Fibrosis Society Patient Registry were utilised.
methodsAnnual data including age, forced expiratory volume in 1 s (FEV
resultsA consistent improvement in FEV
conclusionThis pan-European analysis demonstrates a consistent improvement in FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.